Tilray Inc (NASDAQ:TLRY – Get Free Report)’s stock price dropped 6.9% on Thursday after Canaccord Genuity Group lowered their price target on the stock from $4.25 to $4.00. Canaccord Genuity Group currently has a buy rating on the stock. Tilray traded as low as $1.88 and last traded at $1.88. Approximately 19,786,891 shares changed hands during mid-day trading, a decline of 31% from the average daily volume of 28,873,145 shares. The stock had previously closed at $2.02.
Other equities analysts have also recently issued research reports about the stock. CIBC lowered their price objective on shares of Tilray from $2.25 to $2.00 and set a “neutral” rating on the stock in a research note on Wednesday. Alliance Global Partners increased their target price on shares of Tilray from $2.25 to $2.75 and gave the stock a “neutral” rating in a report on Friday, April 5th.
View Our Latest Research Report on Tilray
Institutional Investors Weigh In On Tilray
Tilray Stock Performance
The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.99 and a current ratio of 1.92. The business’s fifty day simple moving average is $1.97 and its 200-day simple moving average is $1.98. The firm has a market capitalization of $1.35 billion, a PE ratio of -4.14 and a beta of 2.36.
About Tilray
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Recommended Stories
- Five stocks we like better than Tilray
- The 3 Best Blue-Chip Stocks to Buy Now
- You Can Follow BlackRock’s Market View for Your Money
- Insider Buying Explained: What Investors Need to Know
- Breakout Alert: Coinbase’s Consolidation Is About To End
- 3 Tickers Leading a Meme Stock Revival
- 3 Key Stocks Helping to Drive the EV Race
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.